-+ 0.00%
-+ 0.00%
-+ 0.00%

Haizheng Pharmaceutical (600267.SH) subsidiary passed the drug GMP compliance inspection

Zhitongcaijing·12/03/2025 09:49:03
Listen to the news

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. Recently, Haizheng Pharmaceutical Nantong Co., Ltd. (“Haizheng Nantong Company”), a wholly-owned subsidiary of the company, received the “Drug GMP Compliance Inspection Notice” (Suzhou Pharmaceutical Supervisory Notice [2025] No. 438) issued by the Jiangsu Drug Administration.

In this drug GMP compliance inspection, the raw drug minocycline hydrochloride was the first drug GMP compliance test before marketing. The corresponding production line passed the GMP compliance inspection for the first time since a new production line was built. Up to now, the total investment in fixed assets related to the above workshop is about 99.16 million yuan, of which approximately 86.3 million yuan (unaudited) has been completed.